HMG-CoA reductase regulation: Use of structurally diverse first half- reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells

Journal of Lipid Research

Volumn 40, Issue 1, 1999, Pages 24-38

  Petras, Stephen F ^a   Lindsey, Saralyn ^a   Harwood, H James ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cholesterol synthesis; Enzyme inhibition; HMG CoA reductase; Metabolic regulation; Squalene synthetase

Indexed keywords

CHOLESTEROL; FARNESOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; SQUALENE; SQUALENE SYNTHASE INHIBITOR; STEROL; ZARAGOZIC ACID A;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

EID: 0032895029     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-2275(20)33336-8     Document Type: Article

References (55)

1. Rodwell, V. W., J. L. Nordstrom, and J. J. Mitschelen. 1976. Regulation of HMG-CoA reductase. Adv. Lipid Res. 14: 1-74.
2. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-430.
3. Brown, M. S., and J. L. Goldstein. 1980. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21: 505-517.
4. Maltese, W. A. 1990. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J. 4: 3319-3328.
5. Hardie, D. G., and D. Carling. 1997. The AMP-activated protein kinase. Fuel gauge of the mammalian cell? Eur. J. Biochem. 246: 259-273.
6. Roitelman, J., and I. Shechter. 1984. Regulation of rat liver HMG-CoA reductase. Evidence for thiol-dependent allosteric modulation of enzyme activity. J. Biol. Chem. 259: 870-877.
7. Roitelman, J., and I. Shechter. 1984. Allosteric activation of rat liver microsomal HMG-CoA reductase by nicotinamide adenine dinucleotides. J. Biol. Chem. 259: 14029-14032.
8. Mitropoulos, K. A., and S. Venkatesan. 1985. Membrane-mediated control of HMG-CoA reductase activity. In Regulation of HMG-CoA Reductase, B. Preiss, editor. Academic Press Inc., Orlando FL. Chapter 1: 1-48.
9. Osborne, T. F. 1991. Single nucleotide resolution of sterol regulatory region in promoter for HMG-CoA reductase. J. Biol. Chem. 266: 13947-13951.
10. Lopez, D., C. M. Chambers, and G. C. Ness. 1997. HMG-CoA reductase inhibitors unmask cryptic regulatory mechanisms. Arch. Biochem. Biophys. 343: 118-122.
11. Bradfute, D. L., and R. D. Simoni. 1994. Non-sterol compounds that regulate cholesterolgenesis. Analogues of farnesyl pyrophosphate reduce HMG-CoA reductase levels. J. Biol. Chem. 269: 6645-6650.
12. Giron, M. D., C. M. Havel, and J. A. Watson. 1993. Isopentenoid synthesis in eukaryotic cells. An initiating role for post-translational control of HMG-CoA reductase. Arch. Biochem. Biophys. 302: 265-271.
13. Peffley, D., and M. Sinensky. 1985. Regulation of HMG-CoA reductase synthesis by a non-sterol mevalonate-derived product in Mev-1 cells. J. Biol. Chem. 260: 9949-9952.
14. Edwards, P. A., S. F. Lan, R. D. Tanaka, and A. M. Fogelman. 1983. Mevalonolactone mediates the rate of synthesis and enhances the rate of degradation of HMG-CoA reductase in rat hepatocytes. J. Biol. Chem. 258: 7272-7275.
15. Nakanishi, M., J. L. Goldstein, and M. S. Brown. 1988. Multivalent control of HMG-CoA reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J. Biol. Chem. 263: 8929-8937.
16. Roitelman, J., and R. D. Simoni. 1992. Distinct sterol and non-sterol signals for the regulated degradation of HMG-CoA reductase. J. Biol. Chem. 267: 25264-25273.
17. Chun, K. T., S. Bar-Nun, and R. D. Simoni. 1990. The regulated degradation of HMG-CoA reductase requires a short-lived protein and occurs in the endoplasmic reticulum. J. Biol. Chem. 265: 22004-22010.
18. Correll, C. C., and P. A. Edwards. 1994. Mevalonic acid-dependent degradation of HMG-CoA reductase in vivo and in vitro. J. Biol. Chem. 269: 633-638.
19. Correll, C. C., L. Ng, and P. A. Edwards. 1994. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of HMG-CoA reductase. J. Biol. Chem. 269: 17390-17393.
20. Giron, M. D., C. M. Havel, and J. A. Watson. 1994. Mevalonate-mediated suppression of HMG-CoA reductase function in α-toxin-perforated cells. Proc. Natl. Acad. Sci. USA. 91: 6398-6402.
21. Meigs, T. E., D. S. Roseman, and R. D. Simoni. 1996. Regulation of HMG-CoA reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol Chem. 271: 7916-7922.
22. Meigs, T. E., and R. D. Simoni. 1997. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphate. Arch. Biochem. Biophys. 345: 1-9.
23. Keller, R. K., Z. Zhao, C. Chambers, and G. C. Ness. 1996. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver. Arch. Biochem. Biophys. 328: 324-330.
24. Hampton, R. Y., and J. Rine. 1994. Regulated degradation of HMG-CoA reductase, an integral membrane protein of the endoplasmic reticulum in yeast. J. Cell Biol. 125: 299-312.
25. Poulter, C. D. 1990. Biosynthesis of non-head-to-tail terpenes. Formation of 1′-1 and 1′-3 linkages. Acc. Chem. Res. 23: 70-77.
26. Poulter, C. D., and H. C. Rilling. 1981. Conversion of farnesyl pyrophosphate to squalene. In Biosynthesis of Isoprenoid Compounds. J. W. Porter and S. L. Spurgeon, editors. J. Wiley and Sons, NT. Volume I, Chapter 8: 413-441.
27. Harwood, H. J., Jr., E. G. Barbacci-Tobin, S. F. Petras, S. Lindsey, and L. D. Pellarin. 1997. 3-(4-Chlorophenyl)-2-(4-diethylamino-ecthoxyphenyl)-A-pentenonitrile monohydrogen citrate and related analogs. Reversible, competitive, first half-reaction squalene synthetase inhibitors. Biochem. Pharmacol. 53: 839-864.
28. Bergstrom, J. D., M. M. Kurtz, D. J. Rew, A. M. Amend, J. D. Karkas, R. G. Bostedor, V. S. Bansal, C. Dufrense, F. L. VanMiddlesworth, O. D. Hensens, J. M. Liesch, D. L. Zink, K. E. Wilson, J. Onishi, J. A. Milligan, G. Bills, L. Kaplan, M. Nallin-Omstead, R. G. Jenkins, L. Huang, M. S. Meinz, L. Quinn, R. W. Burg, Y. L. Kong, S. Mochales, M. Mojena, I. Martin, F. Pelaez, M. T. Diez, and A. W. Alberts. 1993. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA. 90: 80-84.
29. Lindsey, S., and H. J. Harwood, Jr. 1995. Inhibition of mammalian squalene synthetase activity by zaragozic acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation. J. Biol. Chem. 270: 9083-9096.
30. Harwood, H. J., Jr. 1995. Protein farnesyltransferase: measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology. Anal. Biochem. 226: 268-278.
31. Harwood, H. J., Jr., Y. J. Greene, and P. W. Stacpoole. 1986. Inhibition of human leukocyte HMG-CoA reductase by ascorbic acid. An effect mediated by the free radical monodehydroascorbate. J. Biol. Chem. 261: 7127-7135.
32. Harwood, H. J., Jr., M. Schneider, and P. W. Stacpoole. 1984. Measurement of human leukocyte microsomal HMG-CoA reductase activity. J. Lipid Res. 25: 967-978.
33. Ciosek, C. P., Jr., D. R. Magnin T. Harrity, J. V. H. Logan, J. K. Dickson, Jr., E. M. Gordon, K. A. Hamilton, K. G. Jolibois, L. K. Kunselman, R. M. Lawrence, K. A. Mookhtiar, L. C. Rich, D. A. Slusarchyk, R. B. Sulsky, and S. A. Biller. 1993. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J. Biol. Chem. 268: 24832-24837.
34. Thompson, J. F., D. E. Danley, S. Mazzalupo, P. M. Milos, M. E. Lira, and H. J. Harwood, Jr. 1998. Truncation of human squalene synthase yields active, chrystalizable protein. Arch. Biochem. Biophys. 350: 283-290.
35. Hasumi, K., K. Tachikawa, K. Sakai, S. Murakawa, N. Voshikawa, S. Kumazawa, and A. Endo. 1993. Competitive inhibition of squalene synthetase by squalestatin I. J. Antibiot. 46: 689-691.
36. Petzinger, E. 1994. Transport of organic aniona in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport. Rev. Physiol. Biochem. Pharmacol. 123: 47-211.
37. Rilling, H. C., and L. T. Chayet. 1985. Biosynthesis of cholesterol. In Sterols and Bile Acids. H. Danielsson and J. Sjovall, editors. Elsevier, NY. Chapter 1, 1-39.
38. Ness, C. C., S. Eales, D. Lopez, and Z. Zhao. 1994. Regulation of HMG-CoA reductase gene expression by sterols and nonsterols in rat liver. Arch. Biochem. Biophys. 308: 420-425.
39. Edwards, P. A., S. F. Lan, and A. M. Fogelman. 1983. Alterations in the rates of synthesis and degradation of rat liver HMG-CoA reductase produced by cholestyramine and mevinolin. J. Biol. Chem. 258: 10219-10222.
40. Bradfute, D. L., C. J. Silva, and R. D. Simoni. 1992. Squalene synthase-deficient mutant of Chinese hamster ovary cells. J. Biol. Chem. 267: 18308-18314.
41. Parker, R. A., B. C. Pearce, R. W. Clark, D. A. Gordon, and J. J. K. Wright. 1993. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of HMG-CoA reductase. J. Biol. Chem. 268: 11230-11238.
42. Ness, G. G., Z. Zhao, and R. K. Keller. 1994. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7α-hydroxylase. Arch. Biochem. Biophys. 311: 277-285.
43. Ness, G. C., Z. Zhao, and R. K. Keller. 1995. Changes in hepatic farnesol levels alter rates of HMG-CoA reductase degradation. FASEB J. 9: A1473.
44. Peffley, D. M., and A. K. Gayen. 1997. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of HMG-CoA reductase synthesis at a posttranscriptional level. Arch. Biochem. Biophys. 337: 251-260.
45. James, G. L., J. L. Goldstein, M. S. Brown, T. E. Rawson, T. C. Somers, R. S. McDowell, C. W. Crowley, B. K. Lucas, A. D. Levinson, and J. C., Marsters, Jr. 1993. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science. 260: 1937-1942.
46. Voziyan, P. A., C. M. Goldner, and G. Melnykovych. 1993. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing cholinephosphotransferase activity. Biochem. J. 296: 757-762.
47. Choi, J. W., E. N. Lundquist, and D. M. Peffley. 1993. Inhibition of protein synthesis in baby hamster kidney cells blocks oxysterol-mediated suppression of HMG-CoA reductase at a post-transcriptional level. Biochem. J. 296: 859-866.
48. Forman, B. M., E. Goode, J. Chen, A. E. Oro, D. J. Bradley, T. Perlmann, D. J. Noonan, L. T. Burka, T. McMorris, W. W. Lamph, R. M. Evans, and C. Weinberger 1995. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 81: 687-693.
49. O'Brien, M. L., S. M. Rangwala, K. W. Henry, C. Weinberger, D. C. Crick, C. J. Waechter, D. R. Feller, and D. J. Noonan. 1996. Convergence of three steroid receptor pathways in the mediation of non-genotoxic hepatocarcinogenesis. Carcinogenesis. 17: 185-190.
50. Bostedor, R. G., J. D. Karkas, B. H. Arison, V. S. Bansal, S. Vaidya, J. I. Germershausen, M. M. Kurtz, and J. D. Bergstrom. 1997. Farnesol-derived dicarboxyllic acids in the urine of animals treated with zaragozic acid A or with farnesol. J. Biol. Chem. 272: 9197-9203.
51. Keller, R. K. 1996. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim. Biophys. Acta. 1303: 169-179.
52. Thelin, A., E. Peterson, J. L. Hutson, A. D. McCarthy, J. Ericsson, and G. Dallner. 1994. Effect of squalestatin 1 on the biosynthesis of the mevalonate pathway lipids. Biochim. Biophys. Acta. 1215: 245-249.
53. Lopez, D., C. M. Chambers, R. K. Keller, and G. C. Ness. 1998. Compensatory responses to inhibition of hepatic squalene synthase. Arth. Biochem. Biophys. 351: 159-166.
54. Amin, D., R. Z. Rutledge, S. N. Needle, H. F. Galczenski, K. Neuenschwander, A. C. Scotese, M. P. Maguire, R. C. Bush, D. J. Hele, G. E. Bilder, and M. H. Perrone. 1997. RPR-107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. 281: 746-752.
55. Harrity, T. W., R. J. George, C. P. Ciosek, Jr., S. A. Biller, V. Chen, J. K. Dickson, O. M. Fryszman, K. J. Jolibois, L. K. Kunselman, R. M. Lawrence, J. V. H. Logan, D. R. Magnin, L. C. Rich, D. A. Slusarchyk, R. B. Sulsky, and R. E. Gregg. 1995. BMS-188494, an orally active squalene synthase inhibitor which lowers cholesterol in animals. In XII International Symposium on Drugs Affecting Lipid Metabolism. Elsevier, Amsterdam. 54.